[How to manage anticoagulation in atrial fibrillation ablation].
There are many randomized trials evaluating non-vitamin K oral anticoagulants (NOAC) in patients with atrial fibrillation ablation. VENTURE AF, RE-CIRCUIT, and recently AXAFA have evaluated the three main NOACs in this indication. Other studies such as ABRIDGE J and AEIOU complemented these results. The management of the anticoagulation in these patients is one of the subjects of the European Society of Cardiology guidelines, as well, as, the EHRA guide recently released. The purpose of this article is to summarize published studies and guidelines.